‘May you live in interesting times,’ goes the old Chinese curse. For those who want strong, well-functioning markets in Europe, we are passing through such a period: political stresses, budgetary pressures and Brexit are all conspiring to pose difficult challenges.
Join us on 8 November 2017 in Brussels for a high-level roundtable discussion – part of a search for solutions we are beginning – focusing on the challenges in the life sciences sector.
For healthcare innovation to thrive across Europe, several conditions are required. Finding new medicines and treatments requires world-class public education and research – collaborating across Europe and the world. Making medical innovations ready for market requires harmonised rules for clinical trials and authorisation, strong intellectual property protection, and deep financial markets. The last step, bringing these innovations into the clinic, has different rules from one health system to the next – but there is still immense opportunity for greater effectiveness through collaboration across Europe. All three of these steps – finding, developing and applying medical innovations – must continue strong for Europeans to remain healthy.
For more details, please contact Lysiane Pons at firstname.lastname@example.org
17:45 – Reception
18:15 – Welcome, Richard L. Hudson, Editor in Chief and Vice Chair, Science|Business
- Q&A with Clare Moody, Member of the European Parliament
18:35 – How do we maintain the conditions for life sciences innovation in the EU?
- Line Matthiessen, Director for Health, DG Research & Innovation, European Commission
- Pascale Augé, CEO, Inserm Transfert
- Anna Sandstrom, Science Relations Director, AstraZeneca
- Annemarie Haverhals, Leader, Value Based Healthcare Program, Santeon
19:15 – Dinner Debate: What are the minimum requirements for a vibrant pan-European health sector – for researchers, start-ups, pharma, doctors, administrators and patients?